Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.18970977
   PubMed Web of Science ®Google Scholar
• Schmedt N, Khil L, Berger K, Riedel O. Incidence of multiple sclerosis in germany: a cohort study applying different case definitions based on claims data. Neuroepidemiology. 2017;49(3–4):91–98.29136628
   PubMed Web of Science ®Google Scholar
• Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13:128.24070256
   PubMed Web of Science ®Google Scholar
• Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27.26563094
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.29353550
   PubMed Web of Science ®Google Scholar
• Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16(4):271–281.28209331
   PubMed Web of Science ®Google Scholar
• Druart C, El Sankari S, van Pesch V. Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Relat Outcome Meas. 2017;9:1–10.29317850
   PubMedGoogle Scholar
• Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17(6):354.25912246
   PubMed Web of Science ®Google Scholar
• Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4(5):460–469.26346796
   PubMed Web of Science ®Google Scholar
• Sørensen PS. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. J Neurol Sci. 2011;311(Suppl 1):S29–34.22206763
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.22591293
   PubMed Web of Science ®Google Scholar
• Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815–e1821.29669908
   PubMed Web of Science ®Google Scholar
• Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology. 2008;70(5):336–343.17914063
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cutter G. Long-term registries: answering tough questions with big data? Neurol Clin Pract. 2016;6(2):97–99.29377024
   PubMedGoogle Scholar
• Bezzini D, Battaglia MA. Multiple sclerosis epidemiology in Europe. Adv Exp Med Biol. 2017;958:141–159.28093712
   PubMed Web of Science ®Google Scholar
• Stein JD, Lum F, Lee PP, Rich WL, Coleman AL. Use of health care claims data to study patients with ophthalmologic conditions. Ophthalmology. 2014;121(5):1134–1141.24433971
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Lang M, Tackenberg B, et al. Clinical and demographic profile of patients receiving fingolimod in clinical practice in Germany and the benefit-risk profile of fingolimod after 1 year of treatment: initial results from the observational, noninterventional study PANGAEA. Neurotherapeutics. 2018;15(1):190–199.29274026
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgun K. Real world lab data: patterns of lymphocyte counts in fingolimod treated patients. Front Immunol. 2018;9:2669.30524432
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgun K. Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up. Front Immunol. 2018;9:1071.29872429
   PubMed Web of Science ®Google Scholar
• Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T. Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLoS One. 2017;12(5):e0173353.28475587
   PubMed Web of Science ®Google Scholar
• Smith MY, Sabido-Espin M, Trochanov A, et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis. J Manag Care Spec Pharm. 2015;21(8):650–660.26233537
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Ehlken B, Limmroth V, et al. Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurol. 2015;15:170.26395989
   PubMed Web of Science ®Google Scholar
• Zettl UK, Bauer-Steinhusen U, Glaser T, et al. Adherence to long-term interferon beta-1b injection therapy in patients with multiple sclerosis using an electronic diary. Adv Ther. 2016;33(5):834–847.27090116
   PubMed Web of Science ®Google Scholar
• Hansen K, Schussel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS One. 2015;10(7):e0133279.26214805
   PubMed Web of Science ®Google Scholar
• Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German pharmacoepidemiological research database. Pharmacoepidemiol Drug Saf. 2011;20(3):258–264.21351307
   PubMed Web of Science ®Google Scholar
• Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17(3):215–223.18200610
   PubMed Web of Science ®Google Scholar
• Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol. 2008;14(3):354.18200659
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50(4):485–489.11889067
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263–281.25623244
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368–1374.18535026
   PubMed Web of Science ®Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(1):78–86.24898925
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.16510744
   PubMed Web of Science ®Google Scholar
• Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K. Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials. Mult Scler Relat Disord. 2016;8:124–130.27456887
   PubMed Web of Science ®Google Scholar
• Buijs S, Krol M, de Voer G. Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. J Comp Eff Res. 2018;7(5):453–462.29775086
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415.20089954
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.20089952
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556.24685276
   PubMed Web of Science ®Google Scholar
• Río J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology. 2004;63(3):525–528.15304586
   PubMed Web of Science ®Google Scholar
• Reeß J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler. 2002;8(1):15–18.11936482
   PubMed Web of Science ®Google Scholar
• Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol. 2014;71(8):954–960.24977406
   PubMed Web of Science ®Google Scholar
• Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790–794.27135594
   PubMed Web of Science ®Google Scholar
• Wijnands JMA, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050–1056.29602795
   PubMed Web of Science ®Google Scholar
• Alba Pale L, Leon Caballero J, Samso Buxareu B, Salgado Serrano P, Perez Sola V. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment. Mult Scler Relat Disord. 2017;17:138–143.29055445
   PubMed Web of Science ®Google Scholar
• de Jong HJI, Kingwell E, Shirani A, et al. Evaluating the safety of beta-interferons in MS: A series of nested case-control studies. Neurology. 2017;88(24):2310–2320.28500224
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–337.15862718
   PubMed Web of Science ®Google Scholar